Due to the significant baseline peripheral vasodilatation in cirrhotic patients, vasodilators such as angiotensin-converting enzyme (ACE) inhibitors are unfeasible to treat CCM, as further vasodilation may lower the mean arterial pressure below the cutoff value (approximately 65 mmHg) that induces kidney injury. This evidence concerns the gene ACE and cerebral cavernous malformation.